Published in Cancer Weekly, August 14th, 2007
"Published data from phase 3 studies and meta-analyses were analyzed by means of a systematic literature search in PubMed and Medline databases. Randomized trials using interferon-alpha (IFN-alpha), interleukin-2 (IL-2), and combinations have produced overall response rates of 4-31%. For IFN-alpha, a modest but...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.